Pulmaquin

December 4, 2017December 4, 2017

FDA Advisory Group Sets Jan. 11 Review Date for Linhaliq, Potential Non-CF Bronchiectasis Therapy

Bronchiectasis, News

A committee of the U.S. Food and Drug Administration (FDA) will meet next month to review an application for Linhaliq to be approved for the treatment of patients with non-cystic fibrosis bronchiectasis ... Read more

August 3, 2017August 3, 2017

Aradigm Asks FDA for New Drug Application for Linhaliq to Treat Bacterial Infection in NCFBE

News

Aradigm is asking the U.S. Food and Drug Administration (FDA) for permission to market its candidate therapy, Linhaliq, to treat non-cystic fibrosis bronchiectasis (NCFBE) with chronic lung infections caused by Pseudomonas aeruginosa. ... Read more

December 6, 2016December 6, 2016

Positive Trial Results of Pulmaquin Reported for Non-CF Bronchiectasis Patients with Chronic Lung Infections

Bronchiectasis, News

Aradigm reported positive results from the ORBIT-3 (NCT01515007 ) and ORBIT-4 (NCT02104245) Phase 3 clinical trials assessing Pulmaquin for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE) in patients with chronic lung infection by Pseudomonas aeruginosa bacteria. The pivotal clinical trials ... Read more

October 13, 2016October 13, 2016

Aradigm Partners to Develop Treatments for Resistant Biofilm Lung Infections

Bronchiectasis, Cystic Fibrosis, News

Aradigm Corporation is collaborating with the University of Sydney in Australia to develop nanotechnologies targeting fungal and bacterial biofilms, a common complication of infections associated with chronic diseases like cystic fibrosis ... Read more

May 16, 2016May 16, 2016

Aradigm’s Candidates for NCFBE Featured at ATS 2016

Bronchiectasis, Cystic Fibrosis, News

The American Thoracic Society (ATS) is hosting the ATS 2016 International Conference through May 18 in San Francisco, Calif. Aradigm, an emerging pharmaceutical focused on drugs for the prevention and ... Read more

October 13, 2015November 6, 2015

Aradigm Announces Completion of Patient Enrollment for Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis

Bronchiectasis, News

Aradigm Corporation, a pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases, recently announced the conclusion of patient enrollment in the ... Read more

September 23, 2015November 6, 2015

Aradigm Completes Patient Enrollment For Phase III Trial To Test Novel non-Cystic Fibrosis Bronchiectasis Therapy

Bronchiectasis, News

Aradigm, an emerging pharmaceutical company dedicated to the development and commercialization of drugs to treat a wide range of respiratory ailments, recently announced the completion of patient enrollment for ORBIT (Once-daily ... Read more

September 11, 2015October 28, 2015

Study Shows Aradigm’s Lipoquin and Pulmaquin As Promising Therapies for Treatment of Pulmonary NTM

News, Pneumonia

In a poster communication that will be presented on September 19, 2015 at the International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) in San Diego, CA, entitled “Treatment of Lung Infection Caused ... Read more

May 14, 2015November 6, 2015

Researchers Report Encouraging Results in Treating Pulmonary Non-Tuberculous Mycobacteria With Liposomal Ciprofloxacin

Bronchiectasis, News

Researchers at Oregon State University, Corvallis (OSU) and pharmaceutical company Aradigm Corporation have found that Aradigm’s investigational products Lipoquin® and Pulmaquin® are capable of significantly reducing the growth of the ... Read more

January 16, 2015November 6, 2015

Aradigm’s Non-Cystic Fibrosis Bronchiectasis Drug Pulmaquin Granted New Patents in Europe and Australia

Bronchiectasis, News

Aradigm Corporation has announced that it recently obtained two new patents providing coverage for formulations of liposomal and free ciprofloxacin in Europe (E.U. Patent No. 2079443) and Australia (AU2012211514). Both patents cover ... Read more